Emory University

Emory University Office of Sponsored Programs Division, a tax-exempt non-profit educational institution headquartered in Atlanta, Georgia, is a major recipient of federal research funding across biomedical sciences, infectious diseases, cancer research, and health services delivery, operating as prime recipient on the vast majority of federal grants and contracts while maintaining a small subcontractor presence.

Emory functions as a prime research recipient on 80% of its federal awards (5,794 of 7,255 total awards tracked) across a portfolio dominated by federal research grants. The institution competes full-and-open; it holds no SBA set-asides. Recent contract work includes a $7.576 billion CDC indefinite delivery/indefinite quantity contract for pediatric COVID-19 vaccine supply under the Vaccine for Children program (awarded March 3, 2026, through February 28, 2031, with Chamblee, Georgia as place of performance), a $74,994 firm fixed-price purchase order from the National Cancer Institute for Digital Slide Archive software integration and support (awarded June 2, 2026, through May 27, 2029), and a $275,000 delivery order from Veterans Integrated Service Network 4 for research core services (awarded January 9, 2026, through January 8, 2027). Emory also holds a basic ordering agreement with the Bureau of Medicine and Surgery effective April 1, 2026, through March 31, 2036, for research support and specialized scientific services.

Emory's federal customer base is concentrated in health research and public health agencies. The top five funding agencies by award count are the National Institutes of Health NIAID (662 awards, $1.6 billion combined potential value), the National Cancer Institute (425 awards, $1.03 billion), the National Heart Lung and Blood Institute (411 awards, $152.6 million), the National Institute on Aging (382 awards), and the CDC Pittsburgh (133 awards, $517.7 million). These five customers account for 41% of recent awards by count and 77% of combined potential value. Award volume has grown significantly: from 413 awards in 2022 to 788 in 2024, though 2025 and 2026 show moderation (628 and 271 awards respectively, reflecting the snapshot date of July 15, 2026).

Federal grant work dominates Emory's portfolio. Representative recent project grants span cancer research (a $636,358 NCI grant for targeting VIP-VPAC signaling in pancreatic cancer; a $602,847 NCI grant examining N-glycan modification as a therapeutic target for triple-negative breast cancer), infectious disease (a $1.273 billion NIAID grant supporting the MISTR+ study on improving telehealth PrEP initiation and retention; a $910 thousand NIAID grant on induction of cellular and humoral immunity against HIV using DNA-lipid nanoparticle technology), neuroscience and aging (a $540,901 NINDS grant on changes in dopamine signaling in advanced Parkinson's disease; a $627,646 NIA grant testing cognitive behavioral therapy for insomnia in dementia dyads), mental health (a $628,380 NIMH grant on dopaminergic and noradrenergic mechanisms of emotion-related memory over development), and environmental health (a $3.055 million NIEHS Superfund grant for the Community-Oriented Action, Science, and Translation Superfund Center in Brunswick, Georgia). The institution also serves as sub-recipient on numerous grants: Emory personnel participate as co-investigators in University of Pennsylvania, Columbia University, Duke University, Northwestern, and other prime awards across epidemiology, clinical trials, and translational research.

Service Contract Inventory data shows SCI-reportable invoicing of $104.5 million across three fiscal years (FY2022–FY2024), with $17.8 million in FY2022, $48.6 million in FY2023, and $38.2 million in FY2024. The FTE trajectory shows 189 FTEs in FY2022, declining to 82.8 in FY2023, then recovering to 125 in FY2024. Government-paid hourly rates on prime service contracts ranged from $0.00/hr at the 10th percentile to $115.81/hr at median to $885.03/hr at the 90th percentile, reflecting a broad mix of research support staff, clinical coordinators, and highly specialized scientific personnel. Across prime contracts in the SCI dataset, subcontractors performed approximately 5% of total contractor hours; 67 named subcontractors appear in the records, indicating selective use of sub-capacity for specialized services.

On contract vehicles, Emory holds or sits on an indefinite delivery contract N0018907GZ046 with 42 task orders valued at $2.2 million, a Vaccine and Treatment Evaluation Units vehicle with 28 task orders worth $72.8 million, and several other IDCs with Navy, Defense, and civilian customers. The top parent vehicle by dollar value (the CDC vaccine procurement) reflects Emory's specialized manufacturing and distribution capabilities in pharmaceutical and vaccine supply.

A recompete cliff of 645 awards (combined potential value $134.6 million) completes within the next 24 months, concentrated in NIH project grants, CDC service contracts, and Defense research awards. Corporate structure includes subsidiary entities: The Emory Clinic Inc. (hospital operations), Emory University (parent entity), and Euep LLC (educational operations). The institution operates as an integrated academic medical research center, with Emory Healthcare system components (Children's Healthcare of Atlanta, Emory University Hospital) serving as both research sites and operational divisions. Emory University is a major anchor institution for federal biomedical and health research, with a diversified grant portfolio spanning basic science, translational research, clinical trials, and service delivery, and competes across unrestricted federal solicitations without set-aside protections.